Last reviewed · How we verify
GSK3862995B
GSK3862995B is a small molecule that targets the SGLT2 receptor.
GSK3862995B is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | GSK3862995B |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, GSK3862995B reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (PHASE2)
- A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |